Entrada Therapeutics (TRDA) Enterprise Value (2020 - 2026)

Entrada Therapeutics' Enterprise Value history runs 7 years deep, the most recent figure standing at -$76.4 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 12.69% year-over-year to -$76.4 million; the TTM figure through Mar 2026 stood at -$76.4 million (down 12.69% YoY), while the FY2025 annual figure was -$91.1 million, up 10.04% from the prior year.
• Enterprise Value was -$76.4 million for Q1 2026 at Entrada Therapeutics, up from -$91.1 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$45.2 million in Q4 2022 to a low of -$263.9 million in Q1 2022.
• Historically, Enterprise Value has averaged -$119.4 million across 5 years, with a median of -$79.7 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Enterprise Value soared 84.49% in 2022, then sank 132.31% in 2024.
• A 5-year view of Enterprise Value shows it stood at -$45.2 million in 2022, then tumbled by 49.7% to -$67.6 million in 2023, then sank by 49.72% to -$101.2 million in 2024, then gained by 10.04% to -$91.1 million in 2025, then advanced by 16.04% to -$76.4 million in 2026.
• The last three Enterprise Value figures came in at -$76.4 million (Q1 2026), -$91.1 million (Q4 2025), and -$93.3 million (Q3 2025), per Business Quant data.